Welcome to our dedicated page for Enlivex news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex stock.
Enlivex Therapeutics Ltd. (ENLV) generates news at the intersection of clinical-stage immunotherapy and digital asset treasury management. Company announcements highlight progress in the development of Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state, and its application in moderate-to-severe knee osteoarthritis. Press releases have detailed positive three- and six-month topline data from the ENX-CL-05-001 Phase I/II trial, including clinically meaningful and statistically significant reductions in pain and improvements in function in age-related primary knee osteoarthritis patients.
Investors following ENLV news will also see updates on Enlivex’s adoption of a digital asset treasury strategy centered on the RAIN token. The company reports that RAIN is the primary asset of its digital asset treasury and describes RAIN as the governance and utility token of a fully decentralized predictions and options protocol built on the Arbitrum network. News items have covered a large private placement intended to fund RAIN token accumulation, an exclusive option agreement to purchase RAIN tokens, and the listing of RAIN on major cryptocurrency exchanges such as KuCoin.
Additional ENLV coverage includes SEC-related disclosures, board and governance changes, shareholder communications, and participation in scientific conferences and investor events. Readers can expect articles on clinical data presentations, new patents related to Allocetra™ in osteoarthritis, shareholder letters outlining strategic roadmaps, and virtual webinars or fireside chats with company leadership and external experts. For those tracking both biotechnology developments in knee osteoarthritis and corporate activity around a RAIN-focused digital asset treasury, the Enlivex news feed provides a consolidated view of the company’s key milestones and strategic decisions.
Enlivex (Nasdaq: ENLV) reported that the Rain Foundation launched an AI agent-ready OpenClaw interface enabling anyone to create a live prediction market from a single prompt. The Foundation also announced a $5 million grant program to fund developers building on the Rain protocol.
Enlivex noted it is a major holder of RAIN in its treasury and highlighted a protocol mechanism that allocates approximately 2.5% of trading volume to automatic buy-and-burn of the RAIN token.
Enlivex (Nasdaq: ENLV) reported 2025 audited results with net income $1.23 billion and diluted EPS $25.48, driven by unrealized appreciation in its treasury and treasury-related derivative assets. The company reported $2.31 billion in treasury assets, $1.93 billion shareholders' equity and $30.0 million in cash and short-term digital investments. Enlivex reiterates a dual strategy combining clinical-stage longevity therapeutics and a prediction-markets-backed treasury model and will host a webcast on March 25, 2026 at 09:00 am ET to discuss results.
Enlivex (Nasdaq: ENLV) closed a $21 million debt financing (net proceeds ~$18.7M) on March 23, 2026, via a convertible note at a fixed conversion price of $2.69175 per share. The company acquired $10 million of RAIN tokens and extended an option to buy more RAIN through Dec 31, 2027. The Board approved a $20 million share repurchase program, subject to regulatory requirements.
Transactions support the company’s treasury and repurchase strategy and may affect capital structure and treasury composition.
Enlivex (Nasdaq: ENLV) received FDA IND clearance on March 23, 2026 to start a global, randomized, double-blind, placebo-controlled Phase 2b trial of Allocetra™ for moderate-to-severe age-related primary knee osteoarthritis.
The clearance follows positive 3- and 6-month Phase 1/2a data in 134 patients showing a statistically significant, durable treatment effect in older patients. The Phase 2b is powered to assess pain and physical function at three and six months plus quality-of-life and mobility endpoints.
Enlivex (Nasdaq: ENLV) announced that its primary treasury asset, the RAIN token, was listed on Kraken effective February 9, 2026. The company says the listing expands token access and aims to enhance secondary market liquidity, price discovery, and accessibility for RAIN users and governance participants.
Kraken serves about 5.7 million users and reported over $2 trillion in 2025 trading volume, making it a major access point for institutional and retail digital-asset trading.
Enlivex (Nasdaq: ENLV) announced that its primary digital treasury asset, the RAIN token, was listed on the WhiteBIT cryptocurrency exchange effective January 21, 2026. The listing is intended to expand regional market access and improve secondary market liquidity for RAIN as part of Enlivex's digital asset treasury strategy. WhiteBIT is described as the largest European crypto exchange by traffic and is part of W Group, which serves more than 35 million customers globally. RAIN functions as the governance and utility token of a decentralized predictions and options protocol on the Arbitrum network that enables users to create, trade, and resolve markets tied to real-world events.
Enlivex Therapeutics (Nasdaq: ENLV) has initiated a voluntary delisting of its ordinary shares from the Tel Aviv Stock Exchange with the last TASE trading day expected to be April 23, 2026 and delisting effective on or about April 26, 2026. The company will continue to trade on Nasdaq under the symbol ENLV and will keep filing public reports with the SEC and Nasdaq.
The board approved the move to operate under a single set of listing requirements, reduce duplicative administrative costs, potentially enhance Nasdaq liquidity, and focus investor relations on U.S. capital markets.
Enlivex (Nasdaq: ENLV) announced that its treasury token RAIN began trading on the KuCoin exchange effective January 6, 2026. The listing places RAIN on a major global venue that serves more than 40 million users and ranks among the top ten cryptocurrency exchanges.
Company commentary says the KuCoin listing is expected to expand global market access and secondary liquidity for Enlivex's primary digital treasury holding. KuCoin offers spot trading, derivatives, and yield services and has a strong user base in Southeast Asia. RAIN is described as the governance and utility token of a decentralized predictions and options protocol on Arbitrum.
Enlivex (Nasdaq: ENLV) will host a virtual fireside chat on December 11, 2025 at 11:00 am ET. Executive Chairman Shai Novik will discuss the company’s plans after a $212,000,000 private placement, including a new digital asset treasury strategy focused on RAIN token accumulation, and updates on advancing clinical development of Allocetra. The event includes a live Q&A and a recorded webcast to be posted on the company’s investor relations site. Investors may submit questions in advance to Enlivex@KCSA.com and must register via the provided link.
Enlivex (Nasdaq and TASE: ENLV) announced the closing of a $212,000,000 private placement on November 26, 2025. The company said it will use net proceeds to implement the world’s first RAIN prediction markets token digital-asset treasury strategy while continuing core operations.
RAIN is described as a decentralized predictions and options protocol on Arbitrum with AI-resolved outcomes and a deflationary Buyback & Burn governance token. The company also appointed Matteo Renzi, former Italian prime minister, to its board of directors. BTIG served as sole placement agent.